MX2012002139A - Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. - Google Patents
Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.Info
- Publication number
- MX2012002139A MX2012002139A MX2012002139A MX2012002139A MX2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A MX 2012002139 A MX2012002139 A MX 2012002139A
- Authority
- MX
- Mexico
- Prior art keywords
- diagnosis
- cmet
- antibody
- detection
- prognosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G01N33/57595—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G01N33/575—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con el campo del pronóstico y/o diagnosis de una enfermedad proliferativa en un paciente. Más específicamente, la invención se relaciona con un novedoso anticuerpo con capacidad para unirse específicamente al receptor cMet humano, como así también las secuencias de aminoácidos y ácidos nucleicos que codifican este anticuerpo. La invención comprende asimismo el uso de dicho anticuerpo y los correspondientes procesos para la detección y diagnóstico de trastornos patológicos oncogénicos hiperproliferativos asociados a la expresión de cMet. En ciertas realizaciones, los trastornos son trastornos oncogénicos asociados a la expresión incrementada del polipéptido cMet con respecto a lo normal o cualquier otra patología asociada a la sobreexpresión de cMet. La invención comprende, por último, productos y/o composiciones o kits que comprenden por lo menos dicho anticuerpo para el pronóstico o diagnóstico de ciertos cánceres.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23586409P | 2009-08-21 | 2009-08-21 | |
| EP09305777A EP2287197A1 (en) | 2009-08-21 | 2009-08-21 | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| US34800510P | 2010-05-25 | 2010-05-25 | |
| PCT/EP2010/062271 WO2011020925A1 (en) | 2009-08-21 | 2010-08-23 | Anti-cmet antibody and its use for the detection and the diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002139A true MX2012002139A (es) | 2012-03-07 |
Family
ID=41571045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002139A MX2012002139A (es) | 2009-08-21 | 2010-08-23 | Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8673302B2 (es) |
| EP (2) | EP2287197A1 (es) |
| JP (1) | JP5951486B2 (es) |
| KR (1) | KR20120051734A (es) |
| CN (1) | CN102639564B (es) |
| AR (1) | AR077901A1 (es) |
| AU (1) | AU2010284944B2 (es) |
| BR (1) | BR112012003759A2 (es) |
| CA (1) | CA2769427C (es) |
| ES (1) | ES2692522T3 (es) |
| IL (1) | IL218202A (es) |
| IN (1) | IN2012DN01322A (es) |
| MX (1) | MX2012002139A (es) |
| NZ (2) | NZ700437A (es) |
| RU (1) | RU2582265C2 (es) |
| SG (1) | SG178339A1 (es) |
| TW (1) | TW201111781A (es) |
| WO (1) | WO2011020925A1 (es) |
| ZA (1) | ZA201202076B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| SG10201408229WA (en) | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
| KR101444837B1 (ko) * | 2011-06-03 | 2014-09-30 | 한국생명공학연구원 | ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도 |
| WO2013043715A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| EP2783217B1 (en) * | 2011-11-21 | 2019-04-24 | Taivex Therapeutics Corporation | Biomarkers for cancers responsive to modulators of hec1 activity |
| SG11201402485UA (en) | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
| GB201121914D0 (en) | 2011-12-20 | 2012-02-01 | Ge Healthcare Ltd | Method for patient selection |
| ES2641444T3 (es) * | 2012-05-09 | 2017-11-10 | Eli Lilly And Company | Procedimiento de preparación de cloruros de 4-[[(benzoil)amino]sulfonil]benzoílo y preparación de acilsulfamoilbenzamidas |
| CA2877573A1 (en) * | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind c-met |
| WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
| US10214593B2 (en) | 2013-04-02 | 2019-02-26 | Samsung Electronics Co., Ltd. | Anti-idiotype antibody against anti-c-MET antibody |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| WO2015031614A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015031626A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Soluble cmet assay |
| WO2015032695A1 (en) * | 2013-09-09 | 2015-03-12 | Ventana Medical Systems, Inc. | Scoring method for mesothelin protein expression |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
| KR20160137599A (ko) | 2014-03-24 | 2016-11-30 | 제넨테크, 인크. | C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계 |
| JP2017524371A (ja) | 2014-05-23 | 2017-08-31 | ジェネンテック， インコーポレイテッド | Ｍｉｔバイオマーカーとその使用方法 |
| US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
| WO2016124568A1 (en) * | 2015-02-03 | 2016-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-rho gtpase conformational single domain antibodies and uses thereof |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| WO2016149535A1 (en) * | 2015-03-18 | 2016-09-22 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
| WO2017135791A1 (en) * | 2016-02-05 | 2017-08-10 | Viromed Co., Ltd. | Anti-c-met antibodies and uses thereof |
| EP3804765A1 (en) | 2016-05-17 | 2021-04-14 | AbbVie Biotherapeutics Inc. | Anti-cmet antibody drug conjugates and methods for their use |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| RU2735918C2 (ru) * | 2018-06-07 | 2020-11-10 | Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" | Набор реагентов для выявления маркера эпителиальных карцином |
| EP3816186A4 (en) * | 2018-06-29 | 2022-04-06 | Suzhou Smartnuclide Biopharmaceutical Co., Ltd. | PD-L1 BINDING POLYPEPTIDES AND USE THEREOF |
| KR102396194B1 (ko) * | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| US20220252603A1 (en) * | 2019-06-06 | 2022-08-11 | Apollomics Inc. (Hangzhou) | Method for treating cancer patients using c-met inhibitor |
| JP7750828B2 (ja) | 2019-09-16 | 2025-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質 |
| JP7510518B2 (ja) | 2020-09-01 | 2024-07-03 | レメゲン シーオー．，エルティーディー． | 抗ｃ－Ｍｅｔ抗体薬物複合体及びその応用 |
| IL300952A (en) * | 2020-09-08 | 2023-04-01 | Ideaya Biosciences Inc | Drug combination and tumor treatment |
| CN119343377A (zh) * | 2022-06-09 | 2025-01-21 | 圣塔安娜生物股份有限公司 | 靶向c-Kit和/或siglec的抗体及其用途 |
| CN120019076A (zh) | 2022-07-30 | 2025-05-16 | 松树治疗公司 | 用于靶向溶酶体降解的组合物及其使用方法 |
| WO2025036355A1 (zh) * | 2023-08-14 | 2025-02-20 | 明慧医药（杭州）有限公司 | 抗c-MET纳米抗体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| AU2002357388A1 (en) * | 2001-12-27 | 2003-07-24 | The United States Of America, As Represented By The Department Of Veterans Affairs | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| US7964365B2 (en) * | 2005-11-08 | 2011-06-21 | The United States of Americam as represented by the Secretary, Department of Health and Human Services | Methods for diagnosing and monitoring the progression of cancer |
| ES2368864T3 (es) * | 2006-02-06 | 2011-11-23 | Metheresis Translational Research Sa | Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US7892770B2 (en) * | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
-
2009
- 2009-08-21 EP EP09305777A patent/EP2287197A1/en not_active Withdrawn
-
2010
- 2010-08-23 EP EP10744608.0A patent/EP2467402B1/en active Active
- 2010-08-23 CA CA2769427A patent/CA2769427C/en active Active
- 2010-08-23 US US13/391,435 patent/US8673302B2/en active Active
- 2010-08-23 TW TW099128075A patent/TW201111781A/zh unknown
- 2010-08-23 BR BR112012003759A patent/BR112012003759A2/pt not_active Application Discontinuation
- 2010-08-23 JP JP2012525183A patent/JP5951486B2/ja active Active
- 2010-08-23 CN CN201080036635.7A patent/CN102639564B/zh active Active
- 2010-08-23 AU AU2010284944A patent/AU2010284944B2/en active Active
- 2010-08-23 SG SG2012009106A patent/SG178339A1/en unknown
- 2010-08-23 WO PCT/EP2010/062271 patent/WO2011020925A1/en not_active Ceased
- 2010-08-23 IN IN1322DEN2012 patent/IN2012DN01322A/en unknown
- 2010-08-23 RU RU2012109004/10A patent/RU2582265C2/ru active
- 2010-08-23 NZ NZ700437A patent/NZ700437A/en unknown
- 2010-08-23 MX MX2012002139A patent/MX2012002139A/es not_active Application Discontinuation
- 2010-08-23 ES ES10744608.0T patent/ES2692522T3/es active Active
- 2010-08-23 KR KR1020127005757A patent/KR20120051734A/ko not_active Withdrawn
- 2010-08-23 NZ NZ598194A patent/NZ598194A/en unknown
- 2010-08-23 AR ARP100103069A patent/AR077901A1/es not_active Application Discontinuation
-
2012
- 2012-02-19 IL IL218202A patent/IL218202A/en active IP Right Grant
- 2012-03-20 ZA ZA2012/02076A patent/ZA201202076B/en unknown
-
2014
- 2014-01-24 US US14/163,501 patent/US20140295452A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010284944B2 (en) | 2016-01-28 |
| US8673302B2 (en) | 2014-03-18 |
| WO2011020925A1 (en) | 2011-02-24 |
| IL218202A0 (en) | 2012-04-30 |
| SG178339A1 (en) | 2012-03-29 |
| RU2012109004A (ru) | 2013-09-27 |
| IN2012DN01322A (es) | 2015-06-05 |
| AU2010284944A1 (en) | 2012-03-08 |
| BR112012003759A2 (pt) | 2017-07-11 |
| JP2013502213A (ja) | 2013-01-24 |
| ZA201202076B (en) | 2012-11-28 |
| EP2467402A1 (en) | 2012-06-27 |
| TW201111781A (en) | 2011-04-01 |
| ES2692522T3 (es) | 2018-12-04 |
| IL218202A (en) | 2017-07-31 |
| RU2582265C2 (ru) | 2016-04-20 |
| EP2467402B1 (en) | 2018-08-01 |
| JP5951486B2 (ja) | 2016-07-13 |
| NZ598194A (en) | 2015-05-29 |
| US20140295452A1 (en) | 2014-10-02 |
| US20120149031A1 (en) | 2012-06-14 |
| CA2769427A1 (en) | 2011-02-24 |
| CN102639564A (zh) | 2012-08-15 |
| EP2287197A1 (en) | 2011-02-23 |
| CN102639564B (zh) | 2015-01-07 |
| KR20120051734A (ko) | 2012-05-22 |
| AR077901A1 (es) | 2011-09-28 |
| CA2769427C (en) | 2020-03-10 |
| NZ700437A (en) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012002139A (es) | Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer. | |
| AR081696A1 (es) | Anticuerpo para el diagnostico y/o pronostico de cancer | |
| CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
| BR112013004673A2 (pt) | biomarcadores e métodos de tratamento. | |
| ATE551073T1 (de) | Markierte hgf-bindende peptide für bildgebung | |
| CO6351801A2 (es) | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| MX358517B (es) | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. | |
| GT200600324A (es) | Nuevos anticuerpos anti-igf-ir y usos de los mismos | |
| NI201200014A (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana | |
| GB0718967D0 (en) | Peptide imaging agents | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| MX358249B (es) | Proteínas de enlace al antígeno il-23 humanas. | |
| MX366965B (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
| BR112012032778A2 (pt) | "proteínas multiespecíficas e multivalentes" | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| DOP2014000199A (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение | |
| EA201591742A1 (ru) | Способ улучшения диагностики заболеваний с использованием измеряемых аналитов | |
| BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
| AR088244A1 (es) | oxMIF COMO MARCADOR DE DIAGNOSTICO | |
| DOP2012000232A (es) | Proteínas de unión a antigeno especificas para el componente amiloide serico p | |
| BR112013027851A2 (pt) | métodos para identificar um indivíduo caucasiano e para determinar uma suscetibilidade do indivíduo caucasiano de ter ou desenvolver a degeneração macular relacionada com a idade, e, kit | |
| BR112013003793A2 (pt) | método de diagnóstico das doenças neurodegenerativas | |
| WO2011085134A8 (en) | Methods and compositions for the diagnosis, prognosis and treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |